Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from …
J Peccatori, A Forcina, R Crocchiolo, L Vago… - Leukemia, 2015 - nature.com
Hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA)
haploidentical family donors is a promising therapeutic option for high-risk hematologic …
haploidentical family donors is a promising therapeutic option for high-risk hematologic …
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from …
J Peccatori, A Forcina, D Clerici, R Crocchiolo, L Vago… - Leukemia, 2014 - europepmc.org
Hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA)
haploidentical family donors is a promising therapeutic option for high-risk hematologic …
haploidentical family donors is a promising therapeutic option for high-risk hematologic …
[PDF][PDF] Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell …
J Peccatori, A Forcina, D Clerici, R Crocchiolo, L Vago… - Leukemia, 2015 - researchgate.net
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option for
many patients with hematologic malignancies. 1 Unfortunately, a considerable proportion of …
many patients with hematologic malignancies. 1 Unfortunately, a considerable proportion of …
[HTML][HTML] Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell …
J Peccatori, A Forcina, D Clerici, R Crocchiolo, L Vago… - LEUKEMIA, 2015 - iris.unisr.it
Hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA)
haploidentical family donors is a promising therapeutic option for high-risk hematologic …
haploidentical family donors is a promising therapeutic option for high-risk hematologic …
[引用][C] Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell …
J Peccatori, A Forcina, D Clerici, R Crocchiolo, L Vago… - LEUKEMIA, 2015 - iris.unipv.it
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from …
J Peccatori, A Forcina, D Clerici, R Crocchiolo… - …, 2015 - publicatt.unicatt.it
Hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA)
haploidentical family donors is a promising therapeutic option for high-risk hematologic …
haploidentical family donors is a promising therapeutic option for high-risk hematologic …
[PDF][PDF] Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell …
J Peccatori, A Forcina, D Clerici, R Crocchiolo, L Vago… - Leukemia, 2015 - academia.edu
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option for
many patients with hematologic malignancies. 1 Unfortunately, a considerable proportion of …
many patients with hematologic malignancies. 1 Unfortunately, a considerable proportion of …
[引用][C] Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell …
J Peccatori, A Forcina, D Clerici, R Crocchiolo, L Vago… - Leukemia, 2014 - cir.nii.ac.jp
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of
regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical …
regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical …
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from …
J Peccatori, A Forcina, D Clerici… - Leukemia …, 2015 - search.ebscohost.com
Hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA)
haploidentical family donors is a promising therapeutic option for high-risk hematologic …
haploidentical family donors is a promising therapeutic option for high-risk hematologic …
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from …
J Peccatori, A Forcina, D Clerici, R Crocchiolo… - …, 2015 - pubmed.ncbi.nlm.nih.gov
Hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA)
haploidentical family donors is a promising therapeutic option for high-risk hematologic …
haploidentical family donors is a promising therapeutic option for high-risk hematologic …